Status epilepticus
Status epilepticus | |
---|---|
Prognosis | ~20% thirty-day risk of death[1] |
Frequency | 40 per 100,000 people per year[2] |
Status epilepticus (SE), or status seizure, is a medical condition consisting of a single
Status epilepticus may occur in those with a history of
Signs and symptoms
Status epilepticus can be divided into two categories: convulsive and nonconvulsive (NCSE).[1]
Convulsive
Convulsive status epilepticus presents an urgent neurological condition, which is characterized by an elongated and uncontrollable onsets of seizures in which a regular pattern of contraction and extension of the arms and legs will be observed from the patient.[1][7] The symptoms can be managed by initially introducing a seizure suppressing medication as the first stage of the treatment, which optimally works only for that stage because any delay will reduce the efficacy of those medications. Convulsive status epilepticus frequently affects the elderly and young children. It is responsible for the mortality of up to 20–30% of elderly patients and 0–3% of young children. Patients who survive initial onset are often left with cognitive and neurological defects.[7]
Generalized
Refractory status epilepticus is defined as status epilepticus that continues despite treatment with benzodiazepines and one antiepileptic drug.[9]
Super-refractory status epilepticus is defined as status epilepticus that continues or recurs 24 hours or more after the onset of anaesthetic therapy, including those cases where status epilepticus recurs on the reduction or withdrawal of anesthesia.[10]
Nonconvulsive
Nonconvulsive status epilepticus is a relatively long duration change in a person's
In the case of
The cases of nonconvulsive status epilepticus are characterized by a long-lasting stupor, staring, and unresponsiveness. Recent studies indicated 50% of cases involve patients that are semi-conscious in a way that they can respond but are confused spontaneously. Only 6% have shown a decelerated thought process. About 44% of cases of nonconvulsive status epilepticus are marked by a prolonged or fragmentary coma.[12]
Causes
This section needs additional citations for verification. (April 2020) |
Only 25% of people who experience seizures or status epilepticus have epilepsy.[13] The following is a list of possible causes:
- Stroke[13]
- Hemorrhage[13]
- Intoxicants[13]or adverse reactions to drugs
- anticonvulsants)
- Insufficient dosage or sudden withdrawal of benzodiazepine(s) medication (akin to alcohol withdrawal); itself a class of antiseizure/anticonvulsant medications
- Consumption of alcoholic beverages while on an anticonvulsant, or alcohol withdrawal
- Dieting or fasting while on an anticonvulsant
- Starting on a new medication that reduces the effectiveness of the anticonvulsant or changes drug metabolism, decreasing its half-life, leading to decreased blood concentrations
- Developing a resistance to an anticonvulsant already being used
- Gastroenteritis while on an anticonvulsant, where lower levels of anticonvulsant may exist in the bloodstream due to vomiting of gastric contents or reduced absorption due to mucosal edema
- Developing a new, unrelated condition in which seizures are coincidentally also a symptom, but are not controlled by an anticonvulsant already used
- Metabolic disturbances—such as affected kidney and liver[13]
- Sleep deprivation of more than a short duration is often the cause of a (usually, but not always, temporary) loss of seizure control
- Dehydration – moderate- to severe, especially when combined with any single factor above
Diagnosis
Diagnostic criteria vary, though most practitioners diagnose as status epilepticus for: one continuous, unremitting seizure lasting longer than five minutes,[14] or recurrent seizures without regaining consciousness between seizures for greater than five minutes.[1] Previous definitions used a 30-minute time limit.[2]
Nonconvulsive status epilepticus is believed to be under-diagnosed.[15]
New-onset refractory status epilepticus (NORSE) is defined as status epilepticus that does not respond to an anticonvulsant and lacks an obvious cause after two days of investigation.[16][17]
Treatments
Benzodiazepines
When given intravenously, lorazepam appears to be superior to diazepam for stopping seizure activity.[5][19] Intramuscular midazolam appears to be a reasonable alternative especially in those who are not in hospital.[5]
The benzodiazepine of choice in North America for initial treatment is lorazepam, due to its relatively long duration of action (2–8 hours) when injected, and particularly due to its rapid onset of action, which is thought to be due to its high affinity for GABA receptors and low lipid solubility. This causes the drug to remain in the vascular compartment. If lorazepam is not available, or intravenous access is not possible, then diazepam should be given.[20] Alternatively, medication, such as glucagon, should be given through the bone (intraosseously).[6]
In several countries outside North America, such as the Netherlands,[21] intravenous clonazepam is regarded as the drug of first choice.[21] Cited advantages of clonazepam include a longer duration of action than diazepam and a lower propensity for the development of acute tolerance than lorazepam.[22] The use of clonazepam for this indication is not recognized in North America, perhaps because it is not available as an intravenous formulation there.[22]
Particularly in children, another popular treatment choice is midazolam, given into the
Phenytoin and fosphenytoin
Phenytoin was once another first-line therapy,[24] although the prodrug fosphenytoin can be administered three times as fast and with far fewer injection site reactions. If these or any other hydantoin derivatives are used, then cardiac monitoring is necessary if they are administered intravenously. Because the hydantoins take 15–30 minutes to work, a benzodiazepine or barbiturate is often coadministered. Because of diazepam's short duration of action, they were often administered together anyway.[25] At present, these remain recommended second-line, follow-up treatments in the acute setting per guidelines by groups like Neurocritical Care Society (United States).[6]
Barbiturates
Before the benzodiazepines were invented, barbiturates were used for purposes similar to benzodiazepines in general. Some are still used today in SE[
Carbamazepine and valproate
Others
If this proves ineffective or if barbiturates cannot be used for some reason, then a
Lidocaine has been used in cases that do not improve with other more typical medications.[32] One concern is that seizures often begin again 30 minutes after it is stopped.[32] Additionally, it is not recommended in those with heart or liver problems.[32]
Prognosis
While sources vary, about 16 to 20% of first-time SE patients die;[6] with other sources indicating between 10 and 30% of such patients die within 30 days.[1] Further, 10-50% of first-time SE patients experience lifelong disabilities.[6] In the 30% mortality figure, the great majority of these people have an underlying brain condition causing their status seizure such as brain tumor, brain infection, brain trauma, or stroke. People with diagnosed epilepsy who have a status seizure also have an increased risk of death if their condition is not stabilized quickly, their medication and sleep regimen adapted and adhered to, and stress and other stimulant (seizure trigger) levels controlled. However, with optimal neurological care, adherence to the medication regimen, and a good prognosis (no other underlying uncontrolled brain or other organic disease), the person—even people who have been diagnosed with epilepsy—in otherwise good health can survive with minimal or no brain damage, and can decrease risk of death and even avoid future seizures.[13]
Prognosis of Refractory status epilepticus
A different prognosis method was developed for Refractory Status Epilepticus (RSE). Prognosis studies have shown that there is no clear structure of the symptoms; since they range from gastrointestinal to flu-like symptoms, which are considered to be mild and only represent 10%, while the remaining majority of 90% of the clinical cases were unknown[clarification needed]. It was found that it takes a period of 1 to 14 days for the patient to reach the prodromal stage in which the episode is yet to come for the first time. It was found that the frequency of those initial seizures starts from a short and inconsistent seizures that lasts for a few hours and may extend to few days. It can simply strike to hundreds of seizures per day, which is the stage that needed an urgent medical intervene in which the patient expected to be in the ICU as soon as possible. Typically focal seizures are the most common among those cases.[33]
Epidemiology
In the United States, about 40 cases of SE occur annually per 100,000 people.[2] This includes about 10–20% of all first seizures.[34]
Prevalence
It was found that status is more prevalence among African Americans than Caucasian Americans by threefolds, in North London , it was found that Asian children have recorded a relatively higher susceptibility of developing the more severe form of febrile seizures which is status: 6.5, these ethnical distribution rates indicates the genetic contribution to the susceptibility of status epilepticus, Also, studies have shown that status epilepticus is more common in males.[34]
Aetiology
Many studies have found out that age is the most related factor to the etiology of status epilepticus, since 52% of febrile seizures was found to be children, while for adults
Research
Allopregnanolone is being studied in a clinical trial by the Mayo Clinic to treat super-resistant status epilepticus.[35]
See also
- Status asthmaticus
- Status angiotensus
References
- ^ PMID 25257739.
- ^ S2CID 5294771.
- ^ Drislane, Frank (19 March 2020). Garcia, Paul; Edlow, Jonathan (eds.). "Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis". UpToDate. 34.2217. Wolters Kluwer.
- ^ PMID 25207925.
- ^ a b c d e f g h i j Drislane, Frank (15 June 2021). Garcia, Paul; Edlow, Jonathan (eds.). "Convulsive status epilepticus in adults: Treatment and prognosis: Initial Treatment". UpToDate. 52.96933. Wolters Kluwer.
- ^
- S2CID 42680232.
- PMID 21939901.
- PMID 21914716.
- ^ PMID 21109103.
- ^ PMID 19605972.
- PMID 21941070.
- S2CID 25684463.
- ^ "NORSE (New Onset Refractory Status Epilepticus) and FIRES (Febrile Infection-Related Epilepsy Syndrome)". National Organization for Rare Disorders. Retrieved 2021-12-07.
- ^ "New-Onset Refractory Status Epilepticus (NORSE)". Epilepsy Foundation. Retrieved 2021-12-07.
- ^ Migdady, I., Rosenthal, E. S., & Cock, H. R. (2022). Management of status epilepticus: a narrative review. Anaesthesia, 77 Suppl 1, 78–91. https://www.researchgate.net/publication/357706108_Management_of_status_epilepticus_a_narrative_review
- S2CID 7677504.
- S2CID 31286223.
- ^ ]
- ^ a b Lawn, Nicholas D; Wijdicks, Eelco FM (2002). "Status epilepticus: A critical review of management options". Neurol J Southeast Asia. 7: 47–59.
- S2CID 42391321.
- ^ S2CID 42219786.
- PMID 11433696.) (French).
{{cite journal}}
: CS1 maint: multiple names: authors list (link - S2CID 29378123.
- PMID 12082068.
- PMID 30387431.
- ^ S2CID 205692349.
- ^
- ^ "A Study Using SAGE-547 for Super Resistant Status Epilepticus". Mayo Clinic. Archived from the original on 2017-03-08. Retrieved 2017-03-07.
External links
- Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society
- Thomas, SanjeevV; Cherian, Ajith (2009). "Status epilepticus". Annals of Indian Academy of Neurology. 12 (3): 140–53. PMID 20174493.